INFLAMMATORY BOWEL DISEASE (IBD)

Asacol

INFLAMMATORY BOWEL DISEASE (IBD)

Asacol

Asacol® 800 mg tablets (mesalazine) is first-line treatment for mild to moderate ulcerative colitis (UC).

Asacol is indicated for the treatment of the inflamed lining of the large bowel (colonic and rectal mucosa) and is the first-line treatment for mild to moderate ulcerative colitis.

The World’s Leading Mesalazine

Asacol contains mesalazine and is available as tablets in 400 and 800mg strengths.

Available in clinics and all major retail pharmacies.

Key Features & Benefits

Maintains clinical remission in 9 out of 10 UC patients at 6 months
Maximum dose where it is needed
Highest mucosal absorption
Remission rate of 90%

Asacol™

Asacol™ (mesalazine) is a medicine for the treatment of the inflamed lining of the large bowel (colonic and rectal mucosa) and is prescribed as a first-line treatment for mild to moderate ulcerative colitis (UC). Asacol is available in tablets in 400 and 800 mg strengths as well as enemas and suppositories. Asacol is available in 50 countries worldwide as Asacol and as Octasa®, Asacolon™ and Fivasa™ in the UK, Ireland and France, respectively. Specific indications and instructions for use vary by country.
Asacol™ 1600mg

Asacol 1600 mg (mesalazine) incorporates the modern OPTICORE technology and is indicated for the treatment of mild to moderate UC. Asacol 1600 is currently available in Denmark, Iceland and Norway under the brand name Asacol and in the Netherlands under the brand name Yaldigo.

Asacol 1600: Important information on ASACOL™ 1600 mg and its use can be found in the summary of product characteristics (SmPC)

Related Brands